New England Peptide Expands Custom Antibody Program - Company Conjugates Polyclonal Antibodies to Gold, Biotin

Gardner, Mass., September 10, 2007 – In an effort to actively expand its custom offerings, New England Peptide, LLC (NEP) is now conjugating polyclonal antibodies to gold and biotin.

“The new conjugation possibilities add to long list of host species and polyclonal protocols that NEP offers,” says Dave Robinson, CEO, “and further NEP’s goal of providing a full suite of polyclonal antibody services.”

“We are committed to meeting customer needs as comprehensively as possibly, while maintaining the quality and service for which NEP has become known,” states Robinson. “Growing the custom antibody program is one key way we can serve our market better.”

According to Robinson, NEP has gained a reputation throughout the peptide industry for quality peptides and exceptional customer service – two ingredients necessary for successful custom polyclonal antibodies. The company provides:

• An ELISA success rate of greater than 99 percent;
• Average ELISA titer of 1:1,100,000;
• 100 percent guaranteed customer satisfaction.

New England Peptide ( designs and manufactures peptide and antibody products for drug discovery organizations worldwide. Headquartered in Gardner, Mass., and founded in 1998, the company specializes in custom peptide synthesis and polyclonal antibody production.



"The phospho-NL-4 Ab is fantastic, so that is great news! We have a VERY exciting study ongoing with it.
Not sure if you saw but the original phospho NL-1 Ab you guys made for us we just published in Nature Neuroscience. Thanks for making great antibodies, and we look forward to keep working with you guys!"
Michael B. PhD – NIH